SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-296114
Filing Date
2020-11-17
Accepted
2020-11-17 17:05:54
Documents
14
Period of Report
2020-11-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d82404d8k.htm   iXBRL 8-K 24075
2 EX-99.1 d82404dex991.htm EX-99.1 4158
6 GRAPHIC g82404g53b10.jpg GRAPHIC 4649
  Complete submission text file 0001193125-20-296114.txt   155320

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fprx-20251117.xsd EX-101.SCH 3073
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fprx-20251117_lab.xml EX-101.LAB 17374
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fprx-20251117_pre.xml EX-101.PRE 10955
7 EXTRACTED XBRL INSTANCE DOCUMENT d82404d8k_htm.xml XML 3258
Mailing Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080
Business Address 111 OYSTER POINT BOULEVARD SOUTH SAN FRANCISCO CA 94080 415-365-5600
FIVE PRIME THERAPEUTICS, INC. (Filer) CIK: 0001175505 (see all company filings)

IRS No.: 260038620 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36070 | Film No.: 201321934
SIC: 2834 Pharmaceutical Preparations